ALENTIS THERAPEUTICS

alentis-therapeutics-logo

Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases.

#SimilarOrganizations #People #Financial #Event #Website #More

ALENTIS THERAPEUTICS

Social Links:

Industry:
Biotechnology Therapeutics

Founded:
2019-01-01

Address:
Basel, Basel-Stadt, Switzerland

Country:
Switzerland

Website Url:
http://www.alentis.ch

Total Employee:
11+

Status:
Active

Total Funding:
184.02 M USD

Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API WordPress Font Awesome Organization Schema Sitelinks Search Box Yoast WordPress SEO Plugin


Similar Organizations

bright-peak-therapeutics-logo

Bright Peak Therapeutics

Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

myeloid-therapeutics-logo

Myeloid Therapeutics

Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies.

scout-bio-logo

Scout Bio

Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.

vintabio-logo

VintaBio

VintaBio is a life sciences company that offers cell and gene therapy manufacturing services.


Current Advisors List

neil-goldsmith_image

Neil Goldsmith Board Chairman @ Alentis Therapeutics
Board_member

rafaele-tordjman_image

Rafaele Tordjman Board of Directors @ Alentis Therapeutics
Board_member
2021-06-15

martin-münchbach_image

Martin Münchbach Board Member @ Alentis Therapeutics
Board_member
2019-01-01

jason-dinges_image

Jason Dinges Board of Directors @ Alentis Therapeutics
Board_member
2021-06-15

naveed-siddiqi_image

Naveed Siddiqi Board Member @ Alentis Therapeutics
Board_member

Current Employees Featured

andrea-pellacani_image

Andrea Pellacani
Andrea Pellacani CEO @ Alentis Therapeutics
CEO
2022-05-01

roberto-iacone_image

Roberto Iacone
Roberto Iacone CEO @ Alentis Therapeutics
CEO
2020-07-01

rizwan-velji_image

Rizwan Velji
Rizwan Velji Chief Business Officer @ Alentis Therapeutics
Chief Business Officer
2023-12-01

tamas-schweighoffer_image

Tamas Schweighoffer
Tamas Schweighoffer CSO @ Alentis Therapeutics
CSO
2019-09-01

thomas-baumert_image

Thomas Baumert
Thomas Baumert Founder and Executive BoD @ Alentis Therapeutics
Founder and Executive BoD

greg-elson_image

Greg Elson
Greg Elson Chief Technology Officer @ Alentis Therapeutics
Chief Technology Officer
2019-07-01

Founder


neil-goldsmith_image

Neil Goldsmith

thomas-baumert_image

Thomas Baumert

Investors List

innosuisse_image

Innosuisse

Innosuisse investment in Grant - Alentis Therapeutics

schroders-capital_image

Schroders Capital

Schroders Capital investment in Series C - Alentis Therapeutics

pureos-bioventures_image

Pureos Bioventures

Pureos Bioventures investment in Series C - Alentis Therapeutics

bpifrance_image

Bpifrance

Bpifrance investment in Series C - Alentis Therapeutics

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series C - Alentis Therapeutics

novo-a-s_image

Novo Holdings

Novo Holdings investment in Series C - Alentis Therapeutics

jeito-capital_image

Jeito Capital

Jeito Capital investment in Series C - Alentis Therapeutics

morningside-technology-ventures_image

Morningside Venture Investments

Morningside Venture Investments investment in Series B - Alentis Therapeutics

bpifrance_image

Bpifrance

Bpifrance investment in Series B - Alentis Therapeutics

high-tech-gründerfonds_image

HTGF | High-Tech Gruenderfonds

HTGF | High-Tech Gruenderfonds investment in Series B - Alentis Therapeutics

Official Site Inspections

http://www.alentis.ch Semrush global rank: 4.75 M Semrush visits lastest month: 1.93 K

  • Host name: linux96.curanet.dk
  • IP address: 94.231.106.215
  • Location: Denmark
  • Latitude: 55.7123
  • Longitude: 12.0564
  • Timezone: Europe/Copenhagen

Loading ...

More informations about "Alentis Therapeutics"

Alentis Therapeutics AG - Swiss Biotech

Alentis develops breakthrough treatments for fibrotic diseases. ... Unlike most therapies Alentis’ approach aims at a direct reversal of disease progression. https://alentis.ch/ [email protected]; Location. Hegenheimermattweg 167A, 4123 …See details»

Team - Alentis Therapeutics

Team Roberto IaconeChief Executive Officer Roberto Iacone joined Alentis in 2020, bringing over 15+ years of life science industry experience.Roberto is a physician-scientist and a serial …See details»

About Alentis Therapeutics

About Alentis Therapeutics The Claudin-1 Company Alentis is the leading biotech company developing anti-Claudin-1 therapies. Claudin-1 is an extraordinary target that plays a key role …See details»

Alentis Therapeutics AG Company Profile - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Alentis Therapeutics AG of Allschwil, BASEL-LAND. Get the latest business insights from Dun & …See details»

Alentis Therapeutics: Contact Details and Business Profile

For more information, please visit us at www.alentis.ch or write to: [email protected] View Top Employees from Alentis Therapeutics Website: https://alentis.ch Employees: 59 (26 on …See details»

Alentis Therapeutics - Crunchbase Company Profile

Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech investigating novel therapeutics for CLDN1+ cancers. Alentis is the pioneering business in the use of anti-CLDN1 ADCs and antibodies to modify and …See details»

Alentis Therapeutics - SIP Basel Area

Alentis is using its portfolio of unique monoclonal antibodies that are highly selective for exposed and non-junctional Claudin-1. Claudin-1 a previously unexploited target that plays a key role in …See details»

Alentis Therapeutics - VentureRadar

Website: https://alentis.ch/ Develops innovative CLDN1-targeted therapies to combat solid tumors and organ fibrosis, enhancing treatment options in oncology and fibrosis sectors. ... IL-11 is …See details»

Alentis Therapeutics | LinkedIn

Alentis Therapeutics | 9.105 Follower:innen auf LinkedIn. We develop breakthrough treatments for Claudin1-positive tumors and organ fibrosis | Alentis Therapeutics, the Claudin-1 (CLDN1) …See details»

Alentis Therapeutics AG - top100startup.ch

04.01.2022 Alentis Therapeutics launches first-in-human clinical studies (startupticker.ch) 16.06.2021 USD67 million for Alentis Therapeutics (startupticker.ch) 15.01.2021 Five …See details»

Board of Directors - Alentis Therapeutics

Board of Directors Luca Santarelli, MDChair Dr. Santarelli has more than 20 years of experience in academic and pharmaceutical R&D, spanning the value chain from discovery research to …See details»

Alentis Therapeutics AG - startupticker.ch

Jul 10, 2024 Alentis Therapeutics AG Alentis Therapeutics, the Claudin-1 company, is a clinical-stage biotech developing breakthrough treatments for Claudin-1 positive tumors and organ …See details»

About ALENTIS THERAPEUTICS AG | DxMultiomics

Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Log In. Sign Up. ALENTIS …See details»

Success story Alentis - BaseLaunch

Alentis was founded in 2018 and was financed, incubated and built in close collaboration between Prof. Thomas Baumert, the scientific founder of Alentis and the team of BaseLaunch. The …See details»

Alentis Appoints Jonathan Freve CFO

Sep 3, 2024 Jon brings more than 25 years of financial experience in the biotech sector Basel, Switzerland – Sept 3, 2024, Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology …See details»

Alentis Therapeutics - Craft

Alentis Therapeutics is a company that discovers and develops medications to treat liver diseases such as liver fibrosis, cirrhosis, and cancer. The company develops platform technologies and …See details»

Alentis Therapeutics starts their first-in-human clinical trial

Jan 6, 2022 Basel, Switzerland., 04 January 2022 — Alentis Therapeutics, AG today announced it has dosed the first cohort of healthy participants in a first-in-human Phase 1 clinical trial of …See details»

Alentis Therapeutics Appoints Dr. Luigi Manenti as Chief Medical ...

Basel, Switzerland – 5 January 2023 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ …See details»

Careers - Alentis Therapeutics

Careers Work at Alentis We are a fast-growing biotech on a mission to develop much-needed new medicines for cancer and fibrosis. Our carefully chosen team values collaboration, hard work …See details»

linkstock.net © 2022. All rights reserved